EGFR and non-small cell lung carcinoma: As such, the combined use of SANT-1 and Gefitinib reduce tumorigenesis and cell proliferation in EGFR-TKI resistant cells, thus confirming that blocking the Hh signaling pathway constitute a synergistic mechanism for the sensitization in front to EGFR-TKIs treatments in NSCLC cells [132].